NeuroVive signs deal with Isomerase Therapeutics; receives the first milestone from Sihuan

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed a collaboration agreement with the UK’s Isomerase Therapeutics to develop the molecules that were recently acquired by the British company from Biotica. In addition, the company´s Asian subsidiary has received the first milestone payment from Sihuan Pharmaceutical (HKEx: 0460), the company´s collaboration partner in China, under a deal signed last year (The Pharma Letter November 21, 2012).

The deal with Isomerase is for the product development and commercialization of the cyclophilin-inhibiting molecules from Biotica. The collaboration will focus on cellular protection for traumatic brain injury and heart attack, as well as the new product NVP018/BC556 for antiviral indications. Isomerase was founded by three members of Biotica´s former senior management team, including the former chief scientific officer, who have experience working with the molecules acquired by NeuroVive earlier this year. Development work will begin during the summer. Financial terms were not disclosed.

Payment from Sihuan